BMI-1

/ SCIENCE / By
  1. … -1 CONVEYS TEMOZOLOMIDE RESISTANCE BY THE INHIBITING DNA DAMAGE RESPONSE PATHWAY THROUGH THE POLYCOMB REPRESSOR Bmi-1
  2. … and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV)-mediated Bmi-1 interference driven by Bmi-1 promoter for gastric …
  3. … butyrate inhibits migration and induces AMPK‐mTOR pathway‐dependent autophagy and ROS‐mediated apoptosis via the miR‐139‐5p/Bmi‐1 axis in human …
  4. … following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of Bmi-1 and immune responses to Bmi-1 …
  5. … inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128
  6. … regulates paclitaxel resistance of ovarian cancer cells-a potential of miR-194 by attenuating paclitaxel resistance through the down-regulation of oncogene Bmi-1
  7. … the centromere complex from HeLa interphase cells: UV‐damaged DNA binding protein 1 (DDB‐1) is a component of the CEN‐complex, while BMI‐1 is transiently co …
  8. … the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting Bmi-1
  9. … with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by Bmi-1
  10. 15 Evaluation of Expression of the Bmi-1 Stem Cell Marker in Sinonasal Melanomas and Its Correlation With the Expression of Cell Cycle Proteins
  11. 40. Bmi-1 GENE SILENCING INFLUENCES CELL ADHESION AND INVASIVE PROPERTIES OF MEDULLOBLASTOMA CELLS VIA INHIBITION OF BMP PATHWAY
  12. A death from cancer signature: Microarray analysis identifies the 11-gene Bmi-1-pathway signature predicting therapy failure and short survival of patients diagnosed …
  13. A novel Bmi-1 inhibitor QW24 for the treatment of stem-like colorectal cancer
  14. A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1
  15. A novel pathway involving Tcf-driven Bcl2 under regulation of Bmi-1 stem cell factor: Role in chemoresistance
  16. A regulatory Bmi 1/let‐7i/ERK 3 pathway controls the motility of head and neck cancer cells
  17. A retrospective review of the prognostic value of ALDH-1, Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma
  18. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes
  19. Abstract A130: Targeting Bmi-1 by the novel Bmi-1 inhibitor PTC596 in acute leukemia
  20. Abstract A261: NPV-LDE-225 (Erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2γnull mice by regulating Bmi-1 and microRNA-128.
  21. Abstract LB-234: Bcl-2, a novel target of Bmi-1 (the stem cell associated factor), induced Wnt signaling: Implications on prostate cancer
  22. Abstract# 1073: Targeting Bmi-1 in prostate cancer stem cells
  23. Abstract# 2185: Ewing family tumors that do not over-express Bmi-1 are a distinct subclass that arise from alternate mechanisms of molecular transformation
  24. Abstract# 2564: Relationship of smoothened (SMO) and Bmi-1 expression to progression free survival and overall survival in patients with resected non-small cell lung …
  25. Abstract# 5604: Bmi-1 protects human oral epithelial cells from ionizing radiation
  26. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of Bmi-1, TIM-3 and CLL-1
  27. Adenovirus-delivered Bmi-1 shRNA
  28. Affect of All-trans Retinoic Acid on Expression of Bmi-1 in A431 Cell Line [J]
  29. Alexa Fluor® 488 Mouse Anti-Human Bmi-1
  30. Alexa Fluor® 647 Mouse Anti-Human Bmi-1
  31. Amplification and construction of its sense and antisense eukaryotic expression vector of transcriptional repressor Bmi-1 gene
  32. An old player on a new playground: Bmi-1 as a regulator of prostate stem cells
  33. Anti-aging and anti-osteoporosis effects of green teen polyphenol in a premature aging model of Bmi-1 knockout mice
  34. Anti-aging effect of transplanted amniotic membrane mesenchymal stem cells in a premature aging model of Bmi-1 deficiency
  35. Anti-proliferation effect of Bmi-1 in U937 cells with siRNA
  36. Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549
  37. Association between Bmi-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in …
  38. Association between the Polycomb Group (PcG) Bmi-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell …
  39. Association of ATM and BMI‐1 genetic variation with breast cancer risk in Han Chinese
  40. Association of Bmi-1 and p16 as prognostic factors for head and neck carcinomas
  41. Association of Bmi-1 expression with clinicopathological features and prognosis of colorectal cancer
  42. Association of Bmi-1 mRNA expression with differentiation, metastasis and prognosis of gastric carcinoma
  43. Association of Elevated Peripheral Blood Micronucleus Frequency and Bmi-1 mRNA Expression with Metastasis in Iranian Breast Cancer Patients
  44. Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma
  45. Attenuation of doxorubicin-induced cardiotoxicity by esculetin through modulation of Bmi-1 expression
  46. B-Cell Lymphoma Cells Overexpressing Bmi-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T …
  47. Biological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice
  48. Bmi 1 is downregulated by the natural compound curcumin, but not by bisdemethoxycurcumin and dimethoxycurcumin
  49. BMI is an important driver of beta-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children.
  50. Bmi-1 absence causes premature brain degeneration
  51. Bmi-1 activation is crucial in hTERT-induced epithelial–mesenchymal transition of oral epithelial cells
  52. Bmi-1 and homologous recombination markers in human breast cancer
  53. Bmi-1 and survivin expression with clinicopathological correlation and prognostic impact in B and T/NK-cell non-Hodgkin lymphoma
  54. Bmi-1 as A Molecular Marker for Prognosis of Pediatric ALL
  55. Bmi-1 autoantibody as a new potential biomarker for cervical carcinoma
  56. Bmi-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma
  57. Bmi-1 blocks the TGF-β-mediated senescence
  58. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
  59. Bmi-1 confers adaptive radioresistance to KYSE-150R esophageal carcinoma cells
  60. Bmi-1 cooperates with Foxg1 to maintain neural stem cell self-renewal in the forebrain
  61. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways
  62. Bmi-1 cooperates with human papillomavirus type 16 E6 to immortalize normal human oral keratinocytes
  63. Bmi-1 deficiency resulted in developmental defects in mouse teeth and mandibles
  64. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation
  65. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells
  66. Bmi-1 downregulates the expression of NF-HEV, a novel cellular protein exhibiting growth suppressive activity
  67. Bmi-1 enhances the radioresistance of cells by suppressing the expression of NADPH oxidase genes
  68. Bmi-1 expression as a new independent prognostic marker of hepatocellular carcinoma
  69. Bmi-1 expression inversely correlates with differentiation but not clinical outcome or CDKN2a expression in Ewing sarcoma family of tumors
  70. Bmi-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia
  71. Bmi-1 expression is increased in dogs suffering from immune-mediated haemolytic anaemia
  72. Bmi-1 expression is inversely correlated with the grading of renal clear cell carcinoma
  73. Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.
  74. Bmi-1 expression modulates non-small cell lung cancer progression
  75. Bmi-1 expression of bone marrow mesenchymal stem cells induced by fluid shear stress mediated with Akt signal molecule
  76. Bmi-1 expression predicts prognosis in salivary adenoid cystic carcinoma and correlates with epithelial-mesenchymal transition–related factors
  77. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue
  78. Bmi-1 Expression Predicts the Progression of Malignant Hematopoietic Stem Cells in Myelodysplastic Syndrome.
  79. Bmi-1 extends proliferative potential of human bronchial epithelial cells while retaining their mucociliary differentiation capacity
  80. Bmi-1 extends the life span of normal human oral keratinocytes by inhibiting the TGF-β signaling
  81. Bmi-1 extends the replicative life span of normal human oral keratinocytes independently of p16INK4A
  82. Bmi-1 functions as a cooperative oncogene in Ewing’s sarcoma.
  83. Bmi-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas
  84. Bmi-1 gene and radiation resistance
  85. Bmi-1 Gene Expression and Its Significance in 66 Leukemia Patients
  86. Bmi-1 gene expression and its significance in leukemia
  87. Bmi-1 gene in regulation of proliferation and survival of human prostate cancer
  88. Bmi-1 induces radioresistance in MCF-7 mammary carcinoma cells
  89. Bmi-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells
  90. Bmi-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death
  91. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation
  92. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal
  93. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
  94. Bmi-1 is a potential therapeutic target in diffuse intrinsic pontine glioma
  95. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells
  96. Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9
  97. Bmi-1 is essential for the oncogenic potential in CD133+ human laryngeal cancer cells
  98. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells
  99. Bmi-1 is highly expressed in M0-subtype acute myeloid leukemia
  100. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells
  101. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
  102. Bmi-1 is useful as a novel molecular marker for predicting progression of
  103. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
  104. Bmi-1 mRNA in plasma from breast cancer patients as possible prognosis marker in advanced pathological stages
  105. Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo
  106. Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation
  107. Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
  108. Bmi-1 Overexpression in 32Dcl3 Cells Suppresses Granulocytic Differentiation and Ameliorates Their Growth under IL-3 Diminished Conditions.
  109. Bmi-1 Overexpression Synergizes with p210-BCR-ABL to Induce Stem Cell and Progenitor Transformation.
  110. Bmi-1 plays a critical role in the protection from acute tubular necrosis by mobilizing renal stem/progenitor cells
  111. Bmi-1 promotes drug resistance and cellular invasion in head and neck cancer stem cells
  112. Bmi-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression
  113. Bmi-1 promotes glioma angiogenesis by activating NF-κB signaling
  114. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer
  115. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence …
  116. Bmi-1 promotes self-renewal of radio-and temozolomide (TMZ)-resistant breast cancer cells
  117. Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway
  118. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells
  119. Bmi-1 promotes the invasion and migration of colon cancer stem cells through the downregulation of E-cadherin
  120. Bmi-1 protects human keratinocytes from ionizing radiation by enhancing DNA repair activity and inhibiting the TGF-b signaling
  121. Bmi-1 Protein Expression in CD34 Positive Acute Myelogenous Leukemia Cells as a Prognostic Factor.
  122. Bmi-1 reduction plays a key role in physiological and premature aging of primary human keratinocytes
  123. Bmi-1 Regulates Autoreactive CD4+ T Cell Survival in Immune Thrombocytopenia Patients
  124. Bmi-1 regulates epithelial-to-mesenchymal transition to promote migration and invasion of breast cancer cells
  125. Bmi-1 Regulates Ex Vivo Self-Renewal of Human Erythroblasts
  126. Bmi-1 regulates extensive erythroid self-renewal
  127. Bmi-1 regulates self-renewal of normal and malignant human mammary stem cells
  128. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro
  129. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells
  130. Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
  131. Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner
  132. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic β-cell proliferation
  133. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1
  134. Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma
  135. Bmi-1 silencing significantly reduces gene expression of DNA damage repair markers in human breast cancer (1047.5)
  136. Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity
  137. Bmi-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma
  138. Bmi-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway
  139. Bmi-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer
  140. Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis.
  141. Bmi-1-Green Fluorescent Protein (GFP)-Knock-In Mice Reveal the Dynamic Regulation of Bmi-1 Expression in Normal and Leukemic Hematopoietic Cells.
  142. Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels
  143. Bmi-1-siRNA Regulates the Proliferation of K562 Leukemia Cells in vitro and in vivo by PTEN/pAKT Pathway
  144. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated Bmi-1 expression in late breast cancer relapses
  145. Bmi-1, stem cells and cancer
  146. Bmi-1, stem cells and prostate carcinogenesis
  147. Bmi-1: a protein expressed in stem cells, specialized cells and tumors of the gastrointestinal tract
  148. Bmi-1: At the crossroads of physiological and pathological biology
  149. Bmi‐1 expression predicts prognosis for patients with gastric carcinoma
  150. Bmi‐1 gene is upregulated in early‐stage hepatocellular carcinoma and correlates with ATP‐binding cassette transporter B1 expression
  151. Bmi‐1 high‐expressing cells enrich cardiac stem/progenitor cells and respond to heart injury
  152. Bmi‑1 induces radioresistance by suppressing senescence in human U87 glioma cells
  153. Bmi‐1 is critical for the proliferation and invasiveness of gastric carcinoma cells
  154. BMI‑1 is important in bufalin‑induced apoptosis of K562 cells
  155. Bmi‐1 is related to proliferation, survival and poor prognosis in pancreatic cancer
  156. BMI‐1 Mediates Estrogen‐Deficiency–Induced Bone Loss by Inhibiting Reactive Oxygen Species Accumulation and T Cell Activation
  157. Bmi‐1 plays a critical role in protection from renal tubulointerstitial injury by maintaining redox balance
  158. Bmi‐1 regulates the migration and invasion of glioma cells through p16
  159. Bmi‐1‐green fluorescent protein‐knock‐in mice reveal the dynamic regulation of bmi‐1 expression in normal and leukemic hematopoietic cells
  160. Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway
  161. BMI‑1, a promising therapeutic target for human cancer
  162. Cadherin switching, Twist, and Bmi-1 expression at the invasive front correlate with aggressive disease in oral squamous cell carcinoma patients: molecular biology …
  163. Can the life span of human marrow stromal cells be prolonged by bmi‐1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation?
  164. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer
  165. Change of SALL4 and Bmi-1 Expression Levels in Hematologic Malignancies
  166. Characterization and chromosomal localization of the human proto-oncogene Bmi-1
  167. Circulating Bmi-1 mRNA as a diagnostic and prognostic biomarker for non-small cell lung cancer
  168. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients
  169. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer
  170. Clinical implications of Bmi-1 in cancer stem cells of laryngeal carcinoma
  171. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma
  172. Clinicopathological and prognostic significance of Bmi‐1 expression in human cervical cancer
  173. Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) Gene and Protein in …
  174. Clinicopathological significance of Bmi-1 overexpression in esophageal cancer: a meta-analysis
  175. Clinicopathological study of Bmi-1 and Mel-18 expression in breast cancer [J]
  176. Cloning of the rat proto-oncogene Bmi-1
  177. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio (chemo) therapy
  178. Coexpression of Bmi-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease
  179. Coexpression of Bmi-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma
  180. Collagen I regulates the self‐renewal of mouse embryonic stem cells through α2β1 integrin‐and DDR1‐dependent Bmi‐1
  181. Combination of circulating CXCR4 and Bmi-1 mRNA in plasma: A potential novel tumor marker for gastric cancer
  182. Combination of hTERT and Bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic …
  183. Combined introduction of Bmi-1 and hTERT immortalizes human adipose tissue-derived stromal cells with low risk of transformation
  184. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the Bmi-1 and ras oncogenes in disease …
  185. Consistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma
  186. Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on K562 cells proliferation.
  187. Construction of eukaryotic expression vector targeting Bmi-1 and its influences on proliferation of SW480 cells
  188. Construction of eukaryotic vector Bmi-1 shRNA and its inhibition in Hela cells [J]
  189. Construction of shRNA-Bmi-1 plasmid and its effect on proliferation of ECA109 cells.
  190. Construction, identification and expression of recombinant eukaryotic vector pEGFP-Bmi-1
  191. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
  192. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1
  193. Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1
  194. Correlation between Bmi-1 and clinicopathological features of colorectal cancer
  195. Correlation between Bmi-1, p16 gene expressions and replicative senescence of fetal bone marrow-derived mesenchymal stem cells
  196. Correlation between Rhoc and Bmi-1 invasiveness and migration and prognostic of esophageal squamous carcinoma
  197. Correlation of Bmi-1 expression and telomerase activity in human ovarian cancer
  198. Correlation of HSP70, P53 and Bmi-1 in hepatitis, cirrhosis and hepatocellular carcinoma
  199. Correlations of Bmi-1 expression and telomerase activity in ovarian cancer tissues
  200. Correspondence re: S. Beá et al., Bmi-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphomas. Cancer Res …
  201. Cow’s Milk Yogurt Modulate Expression of STAT5, Bmi-1 and LGR-5 in ileum of Indomethacine-Induced Inflammatory Bowel Disease (IBD) in Rats.
  202. Crucial Role of the Polycomb Group Gene Product Bmi-1 in the Maintenance of Self-Renewing Hematopoietic Stem Cells
  203. Defects in mesenchymal stem cell self‐renewal and cell fate determination lead to an osteopenic phenotype in Bmi‐1 null mice
  204. Deletion of Bmi-1 gene leads to skin aging in mice [J]
  205. Depletion of Bmi-1 enhances 5-fluorouracil-induced apoptosis and autophagy in hepatocellular carcinoma cells
  206. Deregulation of Bmi-1 is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma
  207. Detection of CD133, Bmi‐1, and ABCG2 in ameloblastic tumors
  208. Detection of circulating Bmi‐1 mRNA in plasma and its potential diagnostic and prognostic value for uterine cervical cancer
  209. Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers
  210. Diagnostic value of combined detection of autoantibodies against p53 and Bmi-1 in lung cancer
  211. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma
  212. DIPG-13. SENSITIVITY OF DIPG CELLS TO Bmi-1 MODULATOR PTC596 IS INDEPENDENT OF EZH2 ACTIVITY
  213. DIPG-18. VALIDATION OF Bmi-1 AS A THERAPEUTIC TARGET IN DIFFUSE INTRINSIC PONTINE GLIOMA
  214. Direct serum assay for cell-free Bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer
  215. Distinct Bmi-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation
  216. Doublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis …
  217. Down-regulation of Bmi-1 by RNA interference in Jurkat cells
  218. Down-Regulation of Bmi-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.
  219. Down‐regulation of BMI‐1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells
  220. Downregulated miR-45 Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer
  221. Downregulation of Bmi-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma
  222. Downregulation of Bmi-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells
  223. Downregulation of Bmi-1 enhances chemosensitivity in breast cancer cells.
  224. Downregulation of Bmi-1 is associated with suppressed tumorigenesis and induced apoptosis in CD44+ nasopharyngeal carcinoma cancer stem-like cells
  225. Downregulation of Bmi-1 suppresses epithelial‑mesenchymal transition in melanoma
  226. Downregulation of hsa_circ_0007534 restricts the proliferation and invasion of cervical cancer through regulating miR-498/Bmi-1 signaling
  227. Downregulation of miR-221,-30d, and-15a contributes to pathogenesis of prostate cancer by targeting Bmi-1
  228. Drosophila genes Posterior Sex Combs and Suppressor two of zeste encode proteins with homology to the murine Bmi-1 oncogene
  229. Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone
  230. Effect of 5-fluorouracil on the expression of Oct4 and Bmi-1 in human breast cancer cell line MCF7
  231. Effect of 5-FU on expression of Bmi-1, Sca-1 and Oct-4 in human breast cancer cell line MDA-MB-468
  232. Effect of Bmi-1 gene overexpression on proliferation of human gastric mucosal epithelial cell line GES-1 [J]
  233. Effect of Bmi-1 on radiosensitization of esophageal carcino-ma cells after silencing of Bmi-1 gene
  234. Effect of Bmi-1-mediated NF-κB signaling pathway on the stem-like properties of CD133+ human liver cancer cells
  235. Effect of gene silencing of Bmi-1 on proliferation regulation of CD44+ nasopharyngeal carcinoma cancer stem-like cells
  236. Effect of shRNA-Mediated Gene Silencing of Bmi-1 Expression on Chemosensitivity of CD44+ Nasopharyngeal Carcinoma Cancer Stem-Like Cells
  237. Effect of silencing Bmi-1 by RNA interference on function of K562 cell line
  238. Effect of silencing Bmi-1 expression in reversing cisplatin resistance in lung cancer cells and its mechanism
  239. Effect of siRNA-mediated silencing Bmi-1 gene expression on the proliferation of lung cancer cell line A549 in vitro and in vivo
  240. Effect of siRNA-mediated silencing Bmi-1 gene expression on the proliferation of lung cancer cell line A549 in vitro and in vivo
  241. Effect of siRNA‐mediated silencing of Bmi‐1 gene expression on HeLa cells
  242. Effects of antisense Bmi-1 RNA on the proliferation of lung cancer cell line A549
  243. Effects of Bmi-1 gene suppression on nasopharyngeal carcinoma cell biology behavior
  244. Effects of Bmi-1 on progression of human glioma SNB19 cells [J]
  245. Effects of Bmi-1 over-expression on HOX family expression and cell cycle in HeLa cells
  246. Effects of Bmi-1 RNAi gene on laryngeal carcinoma Hep-2 cells
  247. Effects of Bmi-1 RNAi gene on laryngeal carcinoma Hep-2 cells [J]
  248. Effects of Bmi-1-siRNA on proliferation of lung adenocarcinoma SPC-A1 cells and its mechanism
  249. Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells
  250. Effects of RNA interfering Bmi-1 on glioma cells proliferation
  251. Effects of siRNA silencing of Bmi-1 expression on proliferation of Hela cells
  252. Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells
  253. Efficient immortalization of primary human cells by p16INK4a‐specific short hairpin RNA or Bmi‐1, combined with introduction of hTERT
  254. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival
  255. Elevated Serum IL-6, IL-8, Monocyte Chemoattractant Protein-1, CRP, and IFN-Levels in 10-to 11-Year-Old Boys with Increased BMI
  256. Enforced Expression of Bmi-1 in Postnatal Human CD34+ Cells Promotes Erythroid Differentiation
  257. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1
  258. Enhanced Self-Renewal of Hematopoietic Stem Cells Mediated by the Polycomb Gene Product, Bmi-1.
  259. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer
  260. Establishment of a U266 cell line with stable Bmi-1 silencing by lentivirus-mediated RNA interference
  261. Establishment of detection method for serum circulating Bmi-1 mRNA and its application in diagnosis of colorectal cancer
  262. EVALUATING THE EXPRESSION OF Bmi-1, AS A NEW MOLECULAR MARKER IN DIAGNOSIS AND CHISSIFICATION OF BLADDER TUMORS
  263. Evaluating the expression of Bmi-1, as a new molecular marker in diagnosis and classification of bladder tumors
  264. Evaluating the mechanism and therapeutic potential of PTC-028, a novel inhibitor of Bmi-1 function in ovarian cancer
  265. Evaluation of potential prognostic value of Bmi-1 gene product and selected markers of proliferation (Ki-67) and apoptosis (p53) in the neuroblastoma group of …
  266. Evaluation of the expression of Bmi-1 stem cell marker in sinonasal melanomas and its correlation with the expression of cell cycle proteins
  267. Ewing tumors that do not over-express Bmi-1 are a distinct molecular subclass with variant biology: A report from the Children’s Oncology Group
  268. Ewing tumors that do not overexpress Bmi-1 are a distinct molecular subclass with variant biology: a report from the Children’s Oncology Group
  269. Ex-Vivo Expansion of Human Cord Blood CD34+ Cells by Overexpression of Bmi-1.
  270. Exacerbation of acute leukemia bearing isolated i (17q) along with proliferation of blasts with high Bmi-1 expression
  271. Expression and associations of TRAF1, Bmi-1, ALDH1, and Lin28B in oral squamous cell carcinoma
  272. Expression and Clinical Significance of Bmi-1 and P14 in Extranodal NK/T-cell Lymphoma
  273. Expression and clinical significance of Bmi-1 in colorectal cancer
  274. Expression and clinical significance of Bmi-1 in gastric carcinoma
  275. Expression and Clinical Significance of Bmi-1 in Rectal Cancer
  276. Expression and Clinical Significance of Bmi-1 Oncogene and Its Protein in Cervical Cancer
  277. Expression and Clinical Significance of Bmi-1 Oncogene in Breast Cancer
  278. Expression and Clinical Significance of Bmi-1 Oncogene in Gastric Carcinoma
  279. Expression and clinical significance of Bmi-1 protein and hTERT protein in non-small cell lung cancer.
  280. Expression and clinical significance of Bmi-1, Caspase-8 protein in primary epithelia ovarian cancer
  281. Expression and clinical significance of Bmi-1, Caspase-8 protein in primary epithelia ovarian cancer [J]
  282. Expression and clinical significance of Bmi-1, cyclin D1 and p16 in gastric carcinoma [J]
  283. Expression and clinical significance of Bmi-1, Mdm2 and Ki-67 in extrahepatic biliary duct carcinoma.
  284. Expression and clinical significance of Bmi-1, Podoplanin and p53 in human thymic epithelial tumor
  285. Expression and clinical significance of Bmi-1, Podoplanin and p53 in human thymic epithelial tumor [J]
  286. Expression and clinicopathological significance of Mel-18 and Bmi-1 in esophageal squamous cell carcinoma
  287. Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma
  288. Expression and distribution patterns of the stem cell marker, nestin, and the stem cell renewal factor, Bmi-1, in normal human nasal mucosa and nasal polyps
  289. Expression and significance of Bmi 1 in pancreatic carcinoma
  290. Expression and significance of Bmi-1 and P16 in colorectal carcinoma patients.
  291. Expression and significance of Bmi-1 and P16 in colorectal carcinoma.
  292. Expression and Significance of Bmi-1 and PCNA in Cutaneous Squamous Cell Carcinoma
  293. Expression and significance of Bmi-1 in breast cancer
  294. Expression and Significance of Bmi-1 in Cervical Cancer
  295. Expression and significance of Bmi-1 in endometrial carcinoma
  296. Expression and significance of Bmi-1 in hepatocellular carcinoma tissue and portal vein tumor thrombus
  297. Expression and significance of Bmi-1 in human colon carcinoma [J]
  298. Expression and significance of Bmi-1 mRNA in acute myeloid leukemia with real-time fluorescent quantitative polymerase chain reaction
  299. Expression and significance of Notch1 and Bmi-1 protein in lung cancer tissue
  300. Expression and significance of the Bmi-1 gene in hepatocellular carcinoma
  301. Expression and significances of Bmi-1 and c-myc in diffuse large B-cell lymphoma
  302. Expression changes in EZH2, but not in Bmi-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer
  303. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer
  304. Expression of an alternate splice form of Bmi-1 in multiple myeloma
  305. Expression of B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 (Bmi-1) and WW Domain-Containing Oxidoreductase (WWOX) in Liver …
  306. Expression of Bmi-1 and EZH2 in tissues adjacent to human epithelial ovarian cancer cells of orthotopic implantation in nude mice
  307. Expression of Bmi-1 and hTERT in breast cancer cell line MDA-MB-468 and their relationship with apoptosis [J]
  308. Expression of Bmi-1 and Mel-18 in breast tissue-a diagnostic marker in patients with breast cancer
  309. Expression of Bmi-1 and p16 gene in transitional cell carcinoma of bladder
  310. Expression of Bmi-1 and p16 in cervical carcinoma carcinogenesis progression and its significance [J]
  311. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma
  312. Expression of Bmi-1 Gene in Children with Acute Leukemia and Its Clinical Significance
  313. Expression of Bmi-1 Gene in Children with Acute Leukemia and Its Clinical Significance [J]
  314. Expression of Bmi-1 gene in esophageal carcinoma cell EC9706 and its effect on cell cycle, apoptosis and migration
  315. Expression of Bmi-1 gene in papillary thyroid carcinoma
  316. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis
  317. Expression of Bmi-1 in gastric cancer and its clinical significance
  318. Expression of Bmi-1 in gastric cancer and its significance [J]
  319. Expression of Bmi-1 in NSCLC and Its Relationship to Clinicopathologic Characters
  320. Expression of Bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival
  321. Expression of Bmi-1 is a prognostic marker in bladder cancer
  322. Expression of Bmi-1 Protein in Esophageal Squamous Cell Carcinoma Tissue and Its Relationship with Invasion and Metastasis
  323. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients
  324. Expression of Bmi-1 Stem Cell Marker and P16 in Sinonasal Melanoma and Its Correlation with Cellular Proliferation
  325. Expression of Bmi-1 Stem Cell Marker and P16 in Sinonasal Melanoma and Its Correlation with Cellular Proliferation
  326. Expression of Bmi-1, p14 ARF and Mdm2 and their clinical significance in colorectal carcinoma
  327. Expression of Bmi-1, P16, and CD44v6 in uterine cervical carcinoma and its clinical significance
  328. Expression of BMI‐1 in normal skin and inflammatory and neoplastic skin lesions
  329. Expression of c-myc, Bmi-1, serum insulin-like growth factor-Ⅰ and insulin-like growth factor binding protein-3 and their significances in diffuse large B-cell lymphoma
  330. Expression of CD44, CD44v9, ABCG2, CD24, Bmi‑1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological …
  331. EXPRESSION OF OCT-4, SOX-2, NANOG, NUCLEOSTEMIN, Bmi-1 AND SOX-9 SELF RENEWAL GENES IN HUMAN UMBILICAL CORD VEIN MESENCHYMAL …
  332. Expression of p120 catenin and Bmi-1 and their clinical significance in invasive mammary ductal carcinoma
  333. Expression of Polycomb Group Proteins EZH2 and Bmi-1 During Progression of Esophageal Squamous Intraepithelial Neoplasia
  334. Expression of polycomb protein BMI‐1 maintains the plasticity of basal bronchial epithelial cells
  335. Expression of Polycomb-group (PcG) protein Bmi-1 predicts prognosis in patients with acute myeloid leukemia
  336. Expression of Proteins P16INK 4a, P53 and Bmi-1 in Hematopoietic Stem Cells of Patients with MDS. the Role of Cellular Senescence.
  337. Expression of SALL4 and Bmi-1 mRNA in acute leukemia
  338. Expression of stemness gene Bmi-1 in hepatocellular carcinoma
  339. Expression of the p16INK4a gene product, methylation of the p16INK4a promoter region and expression of the polycomb-group gene Bmi-1 in squamous cell lung …
  340. Expression of the polycomb group gene Bmi-1 in the early chick embryo
  341. Expression Of The Stem Cell Markers ABCG2/BCRP, Bmi-1, P63alpha And C/EBPdelta In The Normal Human Cornea: An Immunohistochemical Study
  342. Expression of VEGF-A/C, VEGF-R2, PDGF-α/β, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma
  343. Expression patterns of ABCG2, Bmi-1, Oct-3/4, and Yap in the developing mouse incisor
  344. Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma
  345. Expression patterns of USP22 and potential targets Bmi-1, PTEN, p-AKT in non-small-cell lung cancer
  346. Expressions and clinical significances of Bmi-1 in human cervical carcinoma [J]
  347. Expressions and clinicopathological significances of Bmi-1 and PADI4 in esophageal squamous cell car-cinoma
  348. EXPRESSIONS OF Bmi-1 AND C-myc PROTEINS IN NON-SMALL CELL LUNG CANCER AND THEIR CORRELATION [J]
  349. EXPRESSIONS OF Bmi-1 AND hTERT PROTEIN IN GASTRIC CARCINOMA
  350. Expressions of Bmi-1 and p53 and significance in colon cancer
  351. EXTH-27. VALIDATION OF Bmi-1 AS A THERAPEUTIC TARGET IN DIFFUSE INTRINSIC PONTINE GLIOMA
  352. EZH2-mediated, but not Bmi-1, epigenetic alteration may be associated with the accelerated cell proliferation and malignant step in IPMN.
  353. flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes Bmi-1.
  354. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression
  355. FoxM1c counteracts oxidative stress-induced senescence in mouse embryonic fibroblasts by up-regulation of Bmi-1 expression
  356. Fuel shipment experience, fuel movements from the Bmi-1 transport cask
  357. Glucagon-like peptide-2 requires a full complement of Bmi-1 for its proliferative effects in the murine small intestine
  358. Harnessing the power of stem cell self-renewal pathways in cancer: Dissecting the role of Bmi-1 in Ewing’s sarcoma initiation and maintenance
  359. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression
  360. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells
  361. HER 2 NEU and Bmi 1 gene expression in Invasive Ductal Carcinoma Breast and Its correlation with hormone receptors and other known prognostic factors
  362. Hes1 promotes cell proliferation and migration by activating Bmi-1 and PTEN/Akt/GSK3β pathway in human colon cancer
  363. Heterozygous knockout of the Bmi-1 gene causes an early onset of phenotypes associated with brain aging
  364. High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma
  365. Id1 and NF-κB promote the generation of CD133+ and Bmi-1+ keratinocytes and the growth of xenograft tumors in mice
  366. Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex
  367. Identification and characterization of Bmi-1-responding element within the human p16 promoter
  368. Identification of a polymorphism in the RING finger of human Bmi-1 that causes its degradation by the ubiquitin–proteasome system
  369. Identification Of Bmi-1 As A Prognostic Marker For Differentiation And Invasiveness Of Retinoblastomas
  370. Identification of genes differentially regulated by E6 in human oral keratinocytes expressing exogenous Bmi-1
  371. IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance
  372. Immortalization of cementoblast progenitor cells with Bmi‐1 and TERT
  373. Immortalization of human oral keratinocytes by Bmi-1 and HPV type 16 E6 requires telomerase activation domain of E6
  374. Immortalized Human Placenta Derived Mesenchymal Cells by Transfection with Bmi-1 Lost the Abilitiy To Differencitate into Cell Types of Osteocytic, Condoricytic and …
  375. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer
  376. Immunohistochemical expression of Bmi-1, S100A4, and claudin-1 in breast cancer
  377. Immunohistochemical expression of cytokeratin 15, cytokeratin 19, follistatin, and Bmi‐1 in basal cell carcinoma
  378. Impaired GLP-1 response predicts prediabetes in obese PCOS with adverse metabolic phenotype independent of BMI
  379. Impaired odontogenic differentiation of senescent dental mesenchymal stem cells is associated with loss of Bmi-1 expression
  380. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas
  381. Implication of USP22 in the regulation of Bmi-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas
  382. In Chronic Myeloid Leukemia Cytotoxic T Cell Responses to Bmi-1 Protein Correlate with Higher Expression of Bmi-1 in Leukemia Progenitors, and May Contribute to …
  383. In vitro study of joint intervention of E-cad and Bmi-1 mediated by transcription activator-like effector nuclease in nasopharyngeal carcinoma
  384. Increased expression of the EZH2 polycomb group gene in Bmi-1-positive neoplastic cells during bronchial carcinogenesis
  385. Increased global long interspersed nucleotide element 1 DNA methylation in type 2 diabetes mellitus individuals relates to lower blood pressure and BMI
  386. Increased levels of circulating and tissue mRNAs of Oct-4, Sox-2, Bmi-1 and Nanog is ESCC patients: potential tool for minimally invasive cancer diagnosis
  387. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma
  388. Independent prognostic value of the basal‐like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI‐1
  389. Inhibiting effect of small interfering RNA of Bmi-1 on the proliferation of breast cancer MCF-7 cells in vitro [J]
  390. Inhibition effect of antisense Bmi-1 on Jurkat cells
  391. Inhibition of Bmi-1 suppressed the tumorigenicity of oral cancer-derived ALDH1-positive cells
  392. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1
  393. Inhibitory Effect of Bmi-1 Knockdown on Growth of Human SO-RB_ (50) Cells In Vitro [J]
  394. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma
  395. Interaction of hedgehog and notch pathways, and Bmi-1 in the regulation of human breast stem cell self-renewal
  396. Intracellular redox status determines self-renewal activity of breast cancer stem-like cells through activation of Nrf2-mediated FoxO3a-Bmi-1 signaling
  397. Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor …
  398. Investigating the role of Bmi-1 in liver growth and function
  399. Investigating the roles of Bmi-1 and IGF-1 in promoting ESFT survival
  400. Investigation of the Correlation Between the Expression and Pathological Eharaeteristies of Bmi-1 Protein in Breast Cancer
  401. Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions: An in vivo and in vitro study
  402. Knock-down of Bmi-1 Arrests HeLa Cells in G_1 Phase
  403. Knockdown of Bmi-1 causes cell-cycle arrest and derepresses p16INK4a, HOXA9 and HOXC13 mRNA expression in HeLa cells
  404. Knockdown of Bmi-1 impairs growth and invasiveness of human gastric carcinoma cells
  405. Knockdown of long noncoding RNA CCAT1 inhibits cell growth, invasion and peritoneal metastasis via downregulation of Bmi-1 in gastric cancer.
  406. Knockdown of the Bmi-1 oncogene inhibits cell proliferation and induces cell apoptosis and is involved in the decrease of Akt phosphorylation in the human breast …
  407. Lentivector-mediated transfer of Bmi-1 and telomerase in muscle satellite cells yields a duchenne myoblast cell line with long-term genotypic and phenotypic stability
  408. Loss of Bmi-1 expression is associated with clinical progress of malignant melanoma
  409. Loss of BMI‐1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD‐2/MyD88‐mediated NF‐κB signaling
  410. Loss of T cell receptor-induced Bmi-1 in the KLRG1+ senescent CD8+ T lymphocyte
  411. Low Bmi-1 expression is associated with an activated Bmi-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma
  412. Lower Bmi-1 expression may predict longer survival of Colon Cancer patients
  413. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells
  414. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins
  415. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation
  416. Microarray analysis of Bmi-1 downstream genes in normal human oral keratinocytes.
  417. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence
  418. MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1
  419. MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and Bmi-1 in cancer stem cells
  420. MicroRNA-128 suppresses prostate cancer by inhibiting Bmi-1
  421. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1
  422. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1
  423. microRNA-186 Suppresses Neural Stem Cell Self-Renewal by Modulating Bmi-1/FOXG1/FOXO3 Network
  424. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene Bmi-1
  425. MicroRNA-200c inhibits epithelial-mesenchymal transition by targeting the Bmi-1 gene through the phospho-AKT pathway in endometrial carcinoma cells in …
  426. MicroRNA-203 increases cell radiosensitivity via directly targeting Bmi-1 in hepatocellular carcinoma
  427. MicroRNA-203 induces apoptosis by targeting Bmi-1 in YD-38 oral cancer cells
  428. MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting Bmi-1
  429. MicroRNA-320a protects against osteoarthritis cartilage degeneration by regulating the expressions of Bmi-1 and RUNX2 in chondrocytes
  430. MicroRNA-330-3p expression indicates good prognosis and suppresses cell proliferation by targeting Bmi-1 in osteosarcoma
  431. MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation
  432. MicroRNA‑183 inhibits gastric cancer proliferation and invasion via directly targeting Bmi‑1
  433. MicroRNA‑200c suppresses cell growth and metastasis by targeting Bmi‑1 and E2F3 in renal cancer cells
  434. MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
  435. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer
  436. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression
  437. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1
  438. miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of Bmi-1 and E2F3
  439. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1
  440. miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells
  441. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1
  442. miR-203 Inhibits the Proliferation and Self-Renewal of Esophageal Cancer Stem-Like Cells by Suppressing Stem Renewal Factor Bmi-1
  443. miR-218 inhibits gastric tumorigenesis through regulating Bmi-1/Akt signaling pathway
  444. miR-218 suppresses the growth of hepatocellular carcinoma by inhibiting the expression of proto-oncogene Bmi-1.
  445. MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1, 6, 7-trihydroxyxanthone on liver cancer cells
  446. MiR-495 promotes senescence of mesenchymal stem cells by targeting Bmi-1
  447. miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1
  448. miR‐376c inhibits cervical cancer cell proliferation and invasion by targeting Bmi 1
  449. miRNA-128 suppresses prostate cancer by inhibiting Bmi-1 to inhibit tumor-initiating cells
  450. Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma
  451. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and Bmi-1, and the corepressor C-terminal-binding protein
  452. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and Bmi-1 Pathways
  453. Nanoparticle siRNA against Bmi-1 with a Polyethylenimine–Laminarin Conjugate for Gene Therapy in Human Breast Cancer
  454. Negative regulation of Bmi-1 by AMPK and implication in cancer progression
  455. Novel anti-Bmi-1 therapy in non-small cell lung cancer
  456. NPV-LDE-225 (Erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.
  457. Nrf2-induced reductive stress favours self-renewal of breast cancer stem-like cells via the FoxO3a-Bmi-1 axis
  458. Nuclear Bmi-1 expression in laryngeal carcinoma correlates with lymph node pathological status
  459. Nucleotide Sequence Of The Feline Bmi-1 Coding Region
  460. Nutritional Intake in Low Body Mass Index (BMI) Males with Type 1 Diabetes and Fibrocalcific Pancreatic Diabetes: What are the Unmet Needs? A Cross …
  461. O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer
  462. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-κB pathway
  463. Oncoprotein BMI‐1 induces the malignant transformation of HaCaT cells
  464. Over-Coexpression of Polycomb Gene EZH2, Bmi-1 and the Phosphorylation of EZH2 in Aorta of Atherosclerosis Rat
  465. Overexpression and lack of copy number variation in the BMI‑1 gene in human glioma
  466. Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase …
  467. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis
  468. Overexpression of Bmi-1 induces the malignant transformation of gastric epithelial cells in vitro
  469. Overexpression of Bmi-1 mRNA predicts the progression and metastasis of liver cancer
  470. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer
  471. Overexpression of Bmi-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma
  472. Overexpression of BMI‐1 correlates with drug resistance in B‐cell lymphoma cells through the stabilization of survivin expression
  473. Overexpression of BMI‐1 is associated with poor prognosis in cervical cancer
  474. Overexpression of Bmi‑1 promotes epithelial‑mesenchymal transition in CD133+ Hep G2 cells
  475. Overexpression of microRNA-132 enhances the radiosensitivity of cervical cancer cells by down-regulating Bmi-1
  476. Overexpression of polycomb protein Bmi-1 in human specimens of breast, ovarian, endometrial and cervical cancer
  477. Overexpression of the Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer
  478. p120E4F-1: A Novel Candidate Factor for Mediating Bmi-1 Function in Hematopoietic Stem Cells.
  479. P16 INK4a Deletion Ameliorated Renal Tubulointerstitial Injury in a Stress-induced Premature Senescence Model of Bmi-1 Deficiency
  480. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation
  481. p21/Cyclin E pathway modulates anticlastogenic function of Bmi‐1 in cancer cells
  482. p38 MAPK-Mediated Bmi-1 down-regulation and defective proliferation in ATM-deficient neural stem cells can be restored by Akt activation
  483. Participation of Bmi-1 protein in cancer.
  484. PerCP-Cy™ 5.5 Mouse Anti-Human Bmi-1
  485. Perturbation of B and T cell development and predisposition to lymphomagenesis in Eμ Bmi 1 transgenic mice require the Bmi1 RING finger
  486. Polycomb and Bmi-1 homologs are expressed in overlapping patterns in Xenopus embryos and are able to interact with each other
  487. Polycomb complex protein Bmi-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and …
  488. Polycomb gene product Bmi-1 regulates stem cell self-renewal
  489. Polygala tenuifolia polysaccharide (PTP) inhibits cell proliferation by repressing Bmi-1 expression and downregulating telomerase activity
  490. Possible Mechanism of Centrosomal Amplification Induced by Oncogene Bmi-1 [J]
  491. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the Bmi-1 proto-oncogene.
  492. Potential Research Tool of Stem Cells from Human Exfoliated Deciduous Teeth: Lentiviral Bmi-1 Immortalization with EGFP Marker
  493. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B
  494. Preclinical studies of Bmi-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma.
  495. Preliminary investigation on expression of Bmi-1 in non-small-cellular lung cancer
  496. Prognostic impact and targeting of Bmi-1 in acute myeloid leukemia
  497. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma
  498. Prognostic role of high Bmi-1 expression in Asian and Caucasian patients with solid tumors: a meta-analysis
  499. Prognostic significance of Bmi-1 but not MEL-18 expression in pulmonary squamous cell carcinoma
  500. Prognostic significance of Bmi-1 expression in patients with esophageal cancer: a meta-analysis
  501. Prognostic value of Bmi-1 oncoprotein expression in non-small cell lung cancer
  502. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study
  503. Prognostic value of FBXO39 and ETS-1 but not Bmi-1 in Iranian colorectal cancer patients
  504. Progress in the Expression of Bmi-1 Gene in Various Tumors
  505. Protein S negatively regulates neural stem cell self-renewal through Bmi-1 signaling
  506. Proto-oncogene Bmi-1 and non-small cell lung cancer
  507. Pyrroloquinoline quinone plays an important role in rescuing Bmi-1-/-mice induced developmental disorders of teeth and mandible–anti-oxidant effect of …
  508. Quantification of human Bmi-1 mRNA with SYBR Green I real-time fluorescent polymerase chain reaction
  509. Quercetin protects against inflammation, MMP‑2 activation and apoptosis induction in rat model of cardiopulmonary resuscitation through modulating Bmi‑1 …
  510. Radioprotective effects of Bmi-1 involve epigenetic silencing of oxidase genes and enhanced DNA repair in normal human keratinocytes
  511. Radiosensitization of esophageal carcinoma cells by the silencing of Bmi-1
  512. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1
  513. Recombinant TAT-Bmi-1 fusion protein induces ex vivo expansion of human umbilical cord blood-derived hematopoietic stem cells
  514. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16INK4a
  515. Reduced miR-128 in breast tumor–initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5
  516. Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation
  517. Regulation of Neural Crest Network Genes by Stem Cell Factor Bmi-1 During Early Chick Development
  518. Regulation of Th2 cell development by Polycomb group gene Bmi-1 through the stabilization of GATA3
  519. Regulatory effects of Bmi-1 gene on self-renewal of hematopoietic stem cells–review
  520. Relationship between B-Cell-specific moloney murine leukemia virus integration site 1 (Bmi-1) and homologous recombination regulatory genes in invasive ductal …
  521. RELATIONSHIP BETWEEN Bmi-1 EXPRESSION AND EPITHELIAL-MESENCHYMAL TRANSITION IN NON-SMALL-CELL LUNG CANCER
  522. Relationship between polycomb‐group protein BMI‐1 and phosphatases regulating AKT phosphorylation level in endometrial cancer
  523. Relationship of Bmi-1 gene expression and human mesenchymal stem cell replication
  524. Research on Bmi-1 gene expression in mesenchymal stem cells and various tumor cells by real-time quantitative PCR [J]
  525. Research Progression of Bmi-1 Oncogene [J]
  526. Risk stratification using Bmi‐1 and Snail expression is a useful prognostic tool for patients with upper tract urothelial carcinoma
  527. RNAi-mediated silencing of the Bmi-1 gene causes growth inhibition and enhances doxorubicin-induced apoptosis in MCF-7 cells
  528. RNAi-silenced human Bmi-1 gene inhibits proliferation of human leukemia cell line K562
  529. Role and characteristic of Bmi-1 in the nervous development and tumorigenesis
  530. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing
  531. Role of Bmi-1 in epigenetic regulation during early neural crest development
  532. Role of Bmi-1 in regulation of ionizing irradiation-induced epithelial-mesenchymal transition and migration of breast cancer cells
  533. Role of Bmi-1 in the proliferation of mesenchymal stem cells derived from umbilical cord blood
  534. Role of Bmi-1 in the self-renewal and proliferation of neural stem cells isolated from human corpus striatum
  535. ROLE OF MEL-18 IN REGULATING PROTEIN SUMOYLATION AND IDENTIFICATION OF A NEW POLYMORPHISM IN Bmi-1
  536. Role of p16INK4a and Bmi-1 in oxidative stress-induced premature senescence in human dental pulp stem cells
  537. Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1
  538. Sequence similarity between the mammalian Bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su (z) 2
  539. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development
  540. ShRNA targeting Bmi-1 sensitizes CD44+ nasopharyngeal cancer stem-like cells to radiotherapy
  541. ShRNA-mediated Bmi-1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis
  542. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib
  543. shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis
  544. Significance and expressions of HIF-1α and Bmi-1 in diffuse large B cell lymphoma
  545. Silencing Bmi-1 enhances the senescence and decreases the metastasis of human gastric cancer cells
  546. Silencing Bmi-1 expression by RNA interference suppresses the growth of laryngeal carcinoma cells
  547. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells
  548. Silencing of Bmi-1 gene enhances chemotherapy sensitivity in human glioblastoma cells
  549. Sodium Butyrate Inhibits Colorectal Cancer Cell Migration by Downregulating Bmi‐1 Through Enhanced miR‐200c Expression
  550. Stem cell divisions controlled by the proto-oncogene Bmi-1.
  551. Stem cell protein BMI‐1 is an independent marker for poor prognosis in oligodendroglial tumours
  552. Stem cell-related proteins C-KIT, C-MYC and Bmi-1 in juvenile nasopharyngeal angiofibroma—do they have a role?
  553. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex
  554. Studies on Metal Complexes as Active Materials in Redox-flow Battery Using Ionic Liquids as Electrolyte: Electrochemical Properties of [Fe (L) x][Tf2N] 2 (L …
  555. Study on Expression of Bmi-1 in Gastric Carcinoma
  556. Synthesis and characterization of 3, 3′-bis (3-maleimidophenyl) phenyl phosphine oxide (BMI)/1, 3-cyanatobenzene epoxy inter-crosslinked matrices for engineering …
  557. Synthesis and diphosphine ligand fluxionality in Os3 (CO) 10 (bmi): Kinetic evidence for nondissociative diphosphine isomerization and X-ray crystal structure of 1, 1 …
  558. Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents
  559. Targeting epigenetic regulator Bmi-1 in alveolar rhabdomyosarcoma
  560. Targeting of Bmi-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
  561. Targeting of Bmi-1 in Mantle Cell Lymphoma
  562. Targeting of Bmi-1 with PTC-209 inhibits glioblastoma development
  563. Targeting of Bmi-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
  564. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal
  565. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency
  566. The associations of Bmi-1 with progression of glomerular chronic kidney disease
  567. The Bmi-1 and mel-18 gene products define a new family of DNA-binding proteins involved in cell proliferation and tumorigenesis
  568. The Bmi-1 helix–turn and ring finger domains are required for Bmi-1 antagonism of (−) epigallocatechin-3-gallate suppression of skin cancer cell survival
  569. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells
  570. The Bmi-1 oncoprotein interacts with dinG and MPh2: the role of RING finger domains
  571. The Bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression
  572. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins
  573. The Bmi-1 oncoprotein overexpression in non-small cell lung cancer is correlated with INK4A-ARF locus downexpression [J]
  574. The Bmi-1 polycomb group gene in skin cancer: regulation of function by (−)–epigallocatechin-3-gallate
  575. The Bmi-1 polycomb protein antagonizes the (−)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival
  576. The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?
  577. The characteristic expression pattern of Bmi-1 and SALL4 genes in placenta tissue and cord blood
  578. The clinicopathological significance of Bmi-1 expression in pathogenesis and progression of gastric carcinomas
  579. The co-expression of USP22 and Bmi-1 may promote cancer progression and predict therapy failure in gastric carcinoma
  580. The conserved HR domain of the Drosophila Suppressor 2 of zeste [Su(z)2] and murine Bmi-1 proteins constitutes a locus-specific chromosome binding domain
  581. The differential expression pattern of the Bmi-1, SALL4 and ABCA3 genes in myeloid leukemia
  582. The Drosophila nielanogaster gene lethal (3) 73Ah encodes a ring finger protein homologous to the oncoproteins MEL-18 and Bmi-1
  583. The Dynamic Expression of Polycomb Gene Bmi-1 in Cultured VSMC in Vitro and Its Correlation with Vascular Smooth Muscle Cell Proliferation and Cell Cycle [J]
  584. The effect of Bmi-1 inhibition on brain cancer stem cells.
  585. The effect of targeting miRNA interfering with Bmi-1 expression on human gallbladder cancer cell proliferation
  586. The expression and prognostic value of stem cell markers Bmi-1, HESC5: 3, and HES77 in human papillomavirus–positive and–negative oropharyngeal squamous …
  587. The expression and significance of Bmi-1 and MMP-9 in colon carcinoma cells [J]
  588. The Expression and Significance of Bmi-1 and Telomerase in Cervical Transformation Process
  589. THE EXPRESSION PATTERN OF Bmi-1 GENE IN ACUTE MYELOID LEUKEMIA
  590. The Feature of SALL4 and Bmi-1 Expression in Placenta and Umbilical Cord Blood
  591. The first-in-class Bmi-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma
  592. THE FIRST-IN-CLASS, ORALLY AVAILABLE Bmi-1 MODULATORS PTC-028 AND PTC596 DISPLAY POTENT ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE …
  593. The knock-down of overexpressed EZH2 and Bmi-1 does not prevent osteosarcoma growth
  594. The novel Bmi-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
  595. The oncogene and Polycomb-group gene Bmi-1 regulates cell proliferation and senescence through the ink4a locus
  596. The polycomb group Bmi-1 gene is a molecular marker for predicting
  597. The Polycomb Group Member Bmi-1 Determines The Proliferative Potential Of CD8 T Cells (B6)
  598. The polycomb group protein Bmi-1 collaborates with H-Ras to promote cellular proliferation and transformation of mammary epithelial cells in vitro, and development …
  599. The polycomb group protein Bmi-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the …
  600. The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells
  601. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial …
  602. The polycomb group proteins, Bmi-1 and EZH2, are tumour-associated antigens
  603. The Polycomb Group Transcriptional Repressor Bmi-1 Is Constitutively Expressed in Multiple Myeloma (MM) Cells and Modulates Proliferation through a Mechanism …
  604. The Polycomb-group homolog Bmi-1 is a regulator of murine Hox gene expression
  605. The potential role of BMI, plasma leptin, nesfatin-1 and ghrelin levels in the early detection of pancreatic necrosis and severe acute pancreatitis: a prospective …
  606. The preliminary study of apoptosis in glioma cells silenced Bmi-1 gene by siRNA
  607. The putative tumor suppressor gene EphA7 is a novel Bmi-1 target
  608. The regulation of p16 expression by the polycomb-group protein Bmi-1 in primary human keratinocytes
  609. The relationship between Bmi-1 and the epithelial–mesenchymal transition in lung squamous cell carcinoma
  610. The role of Bmi-1 gene in submandibular gland of mice
  611. The role of Bmi-1 in benzyl isothiocyanate-mediated suppression of breast cancer stem cell self-renewal
  612. The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate
  613. The SALL4/Bmi-1 expression and clinical significance in multiple myeloma [J]
  614. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1· 2 million participants
  615. The siRNA-mediated silencing of Bmi-1 promotes apoptosis and inhibits invasion of MCF-7 breast cancer cells
  616. The stem cell marker Bmi-1 is sensitive in identifying early lesions of carcinoma ex pleomorphic adenoma
  617. The Study of SALL4 Gene and Bmi-1 Gene Expression in Acute Myeloid Leukemia Patients
  618. The treatment effects and mechanisms of pyrroloquinoline quinone on defective teeth and mandible in Bmi-1 knockout mice
  619. The value of EZH2, p27kip1, Bmi-1 and MIB-1 on biopsy specimens with low risk PC in selecting men with significant prostate cancer at prostatectomy
  620. The value of EZH2, p27kip1, BMI‐1 and MIB‐1 on biopsy specimens with low‐risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
  621. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells
  622. Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression
  623. Transcriptional regulatory effects of Bmi-1 on stemness-associated genes in embryonic stem cells
  624. Transcriptional repression of Sin3B by Bmi-1 prevents cellular senescence and is relieved by oncogene activation
  625. Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity.
  626. Transformation of axial skeleton due to overexpression of Bmi-1 in transgenic mice
  627. Tumor suppressive role of Bmi-1 through inhibition of JAK-STAT signaling in leukemia
  628. Two stem cell markers, ATP‐binding cassette, G2 subfamily (ABCG2) and BMI‐1, predict the transformation of oral leukoplakia to cancer: A long‐term follow‐up study
  629. Ubap2l-Bmi-1-Rnf2 Define a Novel Polycomb Complex Essential For Self-Renewal Of Hematopoietic Stem Cells
  630. Up-regulation of microRNA-16 in glioblastoma inhibits the function of endothelial cells and tumor angiogenesis by targeting Bmi-1
  631. Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia
  632. USP12 regulates cell cycle progression by involving c-Myc, cyclin D2 and Bmi-1
  633. USP22 acts as an oncogene by the activation of Bmi-1-mediated INK4a/ARF pathway and Akt pathway
  634. Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic study
  635. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer

Related Posts

Shopping Cart
Scroll to Top